Israeli machine-learning radiology firm Zebra Medical Vision said today it raised $30 million in a Series C round of financing.
The Series C round was led by aMoon Ventures and joined by Aurum, Johnson & Johnson (NYSE:JNJ) Innovation JJDC, Intermountain Healthcare, Khosla Ventures, NVIDIA, Marc Benioff, OurCrowd and Dolby Ventures, Zebra Medical Vision said. AI scientists Fei Fei Lee and Richard Socher also joined the offering.
“Medical experts worldwide are facing a critical challenge in handling overwhelming demand. We are excited to partner with the Zebra-Med team, which is harnessing the power of data and machine learning to provide physicians and healthcare systems with tools to dramatically increase capacity, while improving patient care. This investment aligns with our vision of backing scalable and sustainable innovations that will have a valuable impact on fundamental facets of global healthcare,” aMoon managing partner Dr. Yair Schindel said in a prepared release.
“I am pleased to partner with Zebra Medical Visions’ distinguished panel of investors. I am a big believer in AI based healthcare solutions and Zebra Medical Vision’s technologies will play a major role in improving the capacity and quality of treatment for patients all over the world,” Aurum Ventures founder & owner Morris Kahn said in prepared remarks.
The company also released results from its Textray chest x-ray research program, which it touted as “the most comprehensive AI research conducted on chest x-rays to date.” The analytics program was trained using approximately 2 million images intended to identify 40 common clinical findings, Zebra said. Results from a study of the program published by Cornell’s University Library.
“I’m extremely proud of our team here at Zebra Medical Vision, that is pushing to develop and release next generation AI products with the commitment to make them affordable to the global market,” Zebra Medical Vision co-founder & CEO Elad Benjamin said in a press release.
In March, Zebra Medical Vision said it won CE Mark approval in the European Union for an algorithm for detecting intracranial hemorrhages as part of its deep learning imaging analytics platform.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.